Dr. Greg Sempowski joined a multi-disciplinary team on a 10 year contract, entitled “Development and Utilization of a Monoclonal Antibody Platform Prototype for Development of Monoclonal Antibodies as Medical Countermeasures Against Threats of Interest.” This contract was awarded to Ology Bioservices, Inc, by the Platforms for Rapid Integrated Solutions for Medical Countermeasures (PRISM) office within the US Department of Defense. The program will target Plague and will focus on producing high quality monoclonal antibodies that will protect individuals who may be exposed to this deadly agent. DHVI faculty member Dr. Mattia Bonsignori will also be involved in this effort.